Company Focus
IQVIA INC.
Latest IQVIA INC. News
Pharmaceutical
Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA. 27 June 2025
Related News
Insights
Company Spotlight
A California-based biotech company aiming to deliver a new class of RNA therapeutics.
Latest News & Features of interest to IQVIA INC.
Biotechnology
Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on June 19, 2025, the European Commission has approved French pharma major Sanofi's (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. 25 July 2025
Biotechnology
Italian family-owned drugmaker Chiesi Farmaceutici and Switzerland’s Serna Bio today announced a global drug discovery and collaboration agreement to discover and develop novel small molecule drugs that target RNA against an undisclosed ‘hard-to-drug’ target of interest for respiratory diseases. 24 July 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved US pharma major AbbVie’s Elahere (mirvetuximab soravtansine) to treat adults with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. 24 July 2025
Biotechnology
Swiss pharma giant Roche has paused shipments of the gene therapy Elevidys (delandistrogene moxeparvovec) for new orders in certain countries outside the USA. 24 July 2025
Biotechnology
US biotech Avidity Biosciences’ stock rose 4% on Wednesday after the company announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota, formerly known as AOC 1044), the company’s investigational therapy for the treatment of people with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). 24 July 2025
Biotechnology
UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia gravis, following positive results in a global Phase III trial that could pave the way for regulatory filings. 24 July 2025
Biotechnology
The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for GSK’s Blenrep (belantamab mafodotin-blmf) combinations for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. 24 July 2025
Pharmaceutical
China remains the most popular country for clinical trials outside North America and Europe in the second quarter (Q2) of 2025, according to a report by the data and analytics company GlobalData. 24 July 2025
Pharmaceutical
Swiss pharma giant Roche this morning released financial results for the first half of 2025, showing that sales grew 7% (+4% in Swiss francs) to 30.9 billion francs ($35.1 billion) due to strong demand for pharmaceutical products. Sales were in line with Visible Alpha consensus of 30.80 billion francs. 24 July 2025
Biotechnology
Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes using its ground-breaking B cell immortalization and screening platform, Kling-Select. 24 July 2025
Latest In Brief for IQVIA INC.
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
French pharma major Sanofi today announced it has entered into an agreement to acquire Vicebio, a privately held biotechnology company headquartered in London, UK. 22 July 2025
18 July 2025
30 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze